Akero Therapeutics, Inc. — Director's Dealing 2021

Jul 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-07-15

Reporting Person: Young Jonathan (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-15	Common Stock	M	9000	$0.615	Acquired	173010	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-15	Employee Stock Option (Right to Buy)	$0.615	M	9000	Disposed	2028-07-29	Common Stock (9000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000	Indirect
Common Stock	20000	Indirect
Common Stock	20000	Indirect

Footnotes

F1: These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F2: 25% of this option vested on August 1, 2018 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.